Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Dermatologic 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Melanoma 320Carcinoma, Non-Small-Cell Lung 73Skin Neoplasms 65Carcinoma, Renal Cell 48Breast Neoplasms 46Lung Neoplasms 45Colorectal Neoplasms 43Neoplasms 41Carcinoma, Basal Cell 41Neoplasm Metastasis 40Squamous Cell Carcinoma of Head and Neck 36Uveal Melanoma 34Ovarian Neoplasms 34Carcinoma, Merkel Cell 32Sarcoma 31Lymphoma, T-Cell, Cutaneous 31Pancreatic Neoplasms 26Prostatic Neoplasms 24Head and Neck Neoplasms 22Stomach Neoplasms 21Thyroid Neoplasms 20Carcinoma, Hepatocellular 20Urinary Bladder Neoplasms 19Uterine Cervical Neoplasms 18Esophageal Neoplasms 18Carcinoma, Squamous Cell 18Mycosis Fungoides 16Carcinoma, Transitional Cell 16Brain Neoplasms 16Recurrence 15

Interventions

Tape Recording 1Opdualag 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Patient Preference × Dermatologic × 90 days × Clear all
NCT05377957 2026-04-15

PROQEM

Leiden University Medical Center

Active not recruiting
500 enrolled
Dermatologic

Uveal Melanoma, Patient Preference

NCT06101134 2026-04-09

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Bristol-Myers Squibb

Phase 2 Active not recruiting
100 enrolled 11 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡